WHO WE ARE

UK leader focused on the research, cultivation,
manufacturing and supply of breakthrough cannabis-based medicines.

AT A GLANCE

100,000 sq ft UK based GMP approved facility comprising a laboratory and indoor hydroponic grow facility

One of the first licenced by the UK regulators and MHRA to produce GMP high-THC medicinal cannabis

MHRA (conditionally) approved clinical trial evaluating the use of cannabis medicines for the management of chronic pain

First-mover advantage to capture large UK opportunity, in a market with significant barriers to entry

£20 million of funding​ received to date to support execution of growth strategy​

Publicly listed on London Stock Exchange (AIM) and the second pharmaceutical cannabis business on the world’s leading growth market since GW Pharma (acquired for $7bn in 2021)

OUR FACILITY

UK’s leading cannabis cultivation and drug development facility

Celadon has a 100,000 sq ft licenced facility based in the West Midlands in the UK. It is an EU-GMP facility with indoor hydroponic cultivation of high-THC cannabis flower, API extraction and an R&D lab for its drug development programme.

The facility has had substantial investment in it and has involved four years of close cooperation with UK regulators and the MHRA to build to EU-GMP standards and the highest level of security.

The facility is being built in three phases:

Phase 1: completed in 2021 with five indoor cultivation rooms, API extraction and R&D lab.
Phase 2: significant addition of indoor cultivation capacity, aiming to be operational in Q1 2023.
Phase 3: further expansion of cultivation and manufacturing capacity, with work targeted in 2024-25.

At full capacity, the facility could produce around 9 tonnes of product.

facility
man in plants
lab 5
CP130722-201

OUR MISSION
& VALUES

Logo

Celadon’s mission is to improve quality of life for patients most in need by developing breakthrough cannabis-based medicines

BOARD & MANAGEMENT

The Board

Alexander Anton

Chairman

Jame Short - Co-Founder

James Short

CEO & Founder

Jonathan Turner

Chief Financial Officer

Robert Barr

Senior Independent NED

Elizabeth Shanahan

Independent NED

David Firth

Independent NED

Dr Steven Hajioff

Independent NED

Senior Leadership Team

Arthur Wakeley

Managing Director

Iqbal Gill

Chief Scientific Officer

Founders

Paul Allen - Founder

Paul Allen

Co-Founder

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Medical Cannabis Market, Transparency Market Research May 2022

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

Stannard et al, (2016) Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

This will close in 0 seconds

 

ENVIRONMENT

Celadon uses a highly controlled indoor cultivation environment in order to produce plants to the tightest pharmaceutical tolerances and cannabinoid content. Hydroponics is used to grow plants in a soilless substrate, with mineral salts dissolved into high quality filtered water and delivered direct to the roots of the plant. Micro-zoned sensors monitor every aspect of the environment in real time; from the room’s temperature, lighting cycles and humidity, to the plant’s mineral absorption and transpiration rates. This allows Celadon to build a data bank of optimal growing conditions for each strain, as well as adjust the room automatically.

TRACKING

Celadon has a bespoke “track and trace” system throughout the production process, providing complete transparency. Each plant is given a unique QR code, allowing it to be traced from its origins through to the final product. IOT boxes are used to automatically feed data into the system, from environmental data to the product’s weight, at each stage of production. This provides full visibility over the production process, as well as inventory tracking and accurate cost analysis which feeds into our accounting systems.

This will close in 0 seconds

Legalised in 2018

This will close in 0 seconds

Legalised in 37 States Limited Federal legalisation

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016

This will close in 0 seconds

Legalised in 2016 Rapid growth to >200k patients (2019-21)

This will close in 0 seconds

Legalised in 2001

This will close in 0 seconds

BUSINESS DESCRIPTION

 

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism.

Its 100,000 sq. ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.

This will close in 0 seconds

COUNTRY OF INCORPORATION/OPERATION

 

Celadon Pharmaceuticals Plc is incorporated in England and Wales and is listed solely on the London Stock
Exchange Alternative Investment Market (AIM), and is subject to the UK City Code on Takeovers and Mergers.

TIDM: CEL.L
ISIN: GB00BDQYGP38

There are no restrictions on the transfer of Celadon Pharmaceutical’s shares.

This will close in 0 seconds

AIM SECURITIES IN ISSUE

 

The following information is correct as at 29th September 2023.

The Company’s issued share capital comprises

61,669,773 ordinary shares

Each with a nominal value of 1 pence

So far as the Company is aware, 44.47% of its issued share capital is not in public hands.

This will close in 0 seconds

Scroll to Top